<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Bone Metab</journal-id><journal-id journal-id-type="iso-abbrev">J Bone Metab</journal-id><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Bone Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2287-6375</issn><issn pub-type="epub">2287-7029</issn><publisher><publisher-name>The Korean Society for Bone and Mineral Research</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27294076</article-id><article-id pub-id-type="pmc">4900960</article-id><article-id pub-id-type="doi">10.11005/jbm.2016.23.2.51</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nho</surname><given-names>Jae-Hwi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Young-Kyun</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ha</surname><given-names>Yong-Chan</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Chung-Hyun</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Suh</surname><given-names>You-Sung</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Koo</surname><given-names>Kyung-Hoi</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Orthopaedic Surgery, Soonchunhyang University Hospital Seoul, Seoul, Korea.</aff><aff id="A2"><label>2</label>Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.</aff><aff id="A3"><label>3</label>Department of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, Korea.</aff><author-notes><corresp>Corresponding author: Young-Kyun Lee. Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea. Tel: +82-31-787-7204, Fax: +82-31-787-4056, <email>ykleemd@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>31</day><month>5</month><year>2016</year></pub-date><volume>23</volume><issue>2</issue><fpage>51</fpage><lpage>54</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2016</year></date><date date-type="rev-recd"><day>08</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 The Korean Society for Bone and Mineral Research</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Although bisphosphonate is effective for the prevention and treatment of osteoporosis, poor medication compliance is a key-limiting factor. We determined whether alarm clock could improve compliance with weekly bisphosphonate in patients with osteoporosis, by comparing with age- and gender-matched control group.</p></sec><sec><title>Methods</title><p>Fifty patients with osteoporosis were recruited and participated in alarm clock group. Patients were asked to take orally weekly risedronate for 1 year, and received alarm clock to inform the time of taking oral bisphosphonate weekly. Using the propensity score matching with age and gender, 50 patients were identified from patients with osteoporosis medication. We compared the compliance with bisphosphonate using medication possession ratio (MPR) between two groups.</p></sec><sec><title>Results</title><p>Although there was no significant difference of baseline characteristics between both groups, the mean MPR (0.80&#x000b1;0.33) of alarm clock group was higher than that (0.56&#x000b1;0.34) of control group (<italic>P</italic>&#x0003c;0.001).</p></sec><sec><title>Conclusions</title><p>Alarming could improve the compliance with weekly oral bisphosphonate in patients with osteoporosis.</p></sec></abstract><kwd-group><kwd>Bisphosphonate osteoporosis</kwd><kwd>Patient compliance</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.[<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref>]</p><p>Bisphosphonate is the most widely used drugs to prevent and treat osteoporosis.[<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref>] Although bisphosphonate is effective for the treatment of osteoporosis and prevention of osteoporotic fractures, poor medication compliance is a key-limiting factor in terms of the prevention and treatment of osteoporosis.[<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref><xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref>] Bisphosphonate-related factors including gastroesophaseal irritation and complex method of ingestion have been well-known risk factors for low compliance with bisphosphonate.[<xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">14</xref>] To overcome poor compliance, new type of bisphosphonate with various dose intervals have introduced. Bisphosphonates with longer interval have shown better compliance.[<xref rid="B15" ref-type="bibr">15</xref><xref rid="B16" ref-type="bibr">16</xref><xref rid="B17" ref-type="bibr">17</xref>]</p><p>However, there have been few intervention studies on improving compliance with bisphosphonate. Our purpose was to determine whether alarm clock could improve compliance with weekly bisphosphonate in patients with osteoporosis, by comparing with age- and gender-matched control group without alarm clock.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a case-control study conducted with prospectively complied data.</p><p>From May 2012 to May 2013, 50 patients with osteoporosis were recruited and participated in alarm clock group. The inclusion criteria were (1) 65 years of age and over, (2) diagnosis of osteoporosis (T-score below -2.5 standard deviation) based on the most recent bone mineral density (BMD) measurements (hip or spine, dual energy X-ray absorptiometry [DXA]), (3) without contraindications to oral bisphosphonate, (4) no cognitive impairment, and (4) ability of interview independently. All eligibility patients were asked to take orally weekly risedronate for 1 year, and received alarm clock to inform the time of taking oral bisphosphonate weekly (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Clocks were provided by Sanofi Aventis. In order to avoid selection bias, written informed consent was not required.</p><p>To obtain control group, the propensity score matching with age and gender was used. As control group, 50 patients, who had taken weekly oral risedronate for treatment of osteoporosis and were followed up for 12 months or more, were identified from patients with osteoporosis medication between 2005 and 2010. The medical records whom they had not received alarm clock in were reviewed to evaluate compliance with bisphosphonate.</p><p>To compare the compliance between two groups, we analyzed compliance with bisphosphonates during 12 months after first prescription. Compliance with bisphosphonates was measured a period of 1 year of treatment after first prescription by using medication possession ratio (MPR) as the parameter.[<xref rid="B9" ref-type="bibr">9</xref><xref rid="B18" ref-type="bibr">18</xref>] MPR was defined as the sum of days of supply of osteoporosis medications divided by the length of follow-up, i.e., 365 days. Compliance was categorized with MPR&#x0003c;80% and MPR&#x02265;80%.[<xref rid="B18" ref-type="bibr">18</xref><xref rid="B19" ref-type="bibr">19</xref>]</p><p>The study protocol was reviewed and approved by the Institutional Review Boards and Ethics Committee.</p><sec><title>1. Statistical analysis</title><p>For statistical analysis, student's t-test was used for continuous data and Pearson's chi-squared test for categorical data. All continuous data are expressed as means and standard deviations (SD). <italic>P</italic>-values&#x0003c;0.05 were considered significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>There was no significant difference of baseline characteristics including age and gender between both groups (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p>The mean MPR (0.80&#x000b1;0.33) of alarm clock group was higher than that (0.56&#x000b1;0.34) of control group (<italic>P</italic>&#x0003c;0.001).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>To our knowledge, this is the first study that evaluates compliance with weekly oral bisphosphonate in patients alarmed with clock. This study presented that alarming could improve the compliance with weekly bisphosphonate in patients with osteoporosis.</p><p>Poor compliance is a major challenge in contemporary therapeutics, because osteoporosis has asymptomatic feature itself like other silent chronic diseases. Higher ages, low socioeconomic status, low awareness on osteoporosis, various interval of administration, and adverse effect of bisphosphonate have been presented to be risk factors for low compliance with bisphosphonate.[<xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">14</xref>] Identifying patients with high risk of low compliance and efforts to increase compliance are very important in treatment of osteoporosis.</p><p>Complex dosing schedules related to other chronic diseases, such as hypertension, hyperlipidemia, and diabetes mellitus could lead to lack of compliance for osteoporosis medication. Simply forgetting to take the medication may also result in non-persistence or non-compliance in old ages.[<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>] In a previous study, 24% of the patients answered that they occasionally forgot to refill a prescription, as the reason why they did not fill prescriptions with drug regimens.[<xref rid="B21" ref-type="bibr">21</xref>] Therefore, it is important to alarm patients taking the medication, not to forget.</p><p>In this study, the MPR (0.56) of oral bisphosphonate without alarm clock is similar with that of another study.[<xref rid="B22" ref-type="bibr">22</xref><xref rid="B23" ref-type="bibr">23</xref>] However, weekly bisphosphonate with alarm clock could improve MPR (0.80) obviously in this study.</p><p>In this study, we used clock with alarming function. Currently, this intervention using alarming can be conducted with smartphone or message service using IT technology.</p><p>There are some limitations. First, we did not perform randomized study, but used historical control group. But, not to intervene control group will be ethical problem. Second, we included only patients with weekly oral bisphosphonate. Third, we did not evaluate the change of BMD and compare the incidence of osteoporotic fracture. Fourth, we did not calculate a sample size prior to study. But, power of this study was 94.5% with type 1 error of 5%.</p><p>This study, which is the first study to intervene for compliance with bisphosphonate, presented that alarming could improve the compliance with weekly bisphosphonate in patients with osteoporosis.</p></sec></body><back><fn-group><fn fn-type="conflict"><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="other"><p>We appreciated Sanofi Aventis providing alarm clocks.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Ha</surname><given-names>YC</given-names></name><name><surname>Jang</surname><given-names>S</given-names></name><etal/></person-group><article-title>The incidence and residual lifetime risk of osteoporosis-related fractures in Korea</article-title><source>J Bone Miner Metab</source><year>2011</year><volume>29</volume><fpage>744</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">21644058</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salaffi</surname><given-names>F</given-names></name><name><surname>Cimmino</surname><given-names>MA</given-names></name><name><surname>Malavolta</surname><given-names>N</given-names></name><etal/></person-group><article-title>The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study</article-title><source>J Rheumatol</source><year>2007</year><volume>34</volume><fpage>1551</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">17516618</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>HK</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Jang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Incidence and mortality following hip fracture in Korea</article-title><source>J Korean Med Sci</source><year>2011</year><volume>26</volume><fpage>1087</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">21860561</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haentjens</surname><given-names>P</given-names></name><name><surname>Autier</surname><given-names>P</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><etal/></person-group><article-title>Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-analysis</article-title><source>J Bone Joint Surg Am</source><year>2003</year><volume>85-a</volume><fpage>1936</fpage><lpage>1943</lpage><pub-id pub-id-type="pmid">14563801</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siris</surname><given-names>ES</given-names></name><name><surname>Selby</surname><given-names>PL</given-names></name><name><surname>Saag</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Impact of osteoporosis treatment adherence on fracture rates in North America and Europe</article-title><source>Am J Med</source><year>2009</year><volume>122</volume><fpage>S3</fpage><lpage>S13</lpage><pub-id pub-id-type="pmid">19187810</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadji</surname><given-names>P</given-names></name><name><surname>Claus</surname><given-names>V</given-names></name><name><surname>Ziller</surname><given-names>V</given-names></name><etal/></person-group><article-title>GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates</article-title><source>Osteoporos Int</source><year>2012</year><volume>23</volume><fpage>223</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">21308365</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landfeldt</surname><given-names>E</given-names></name><name><surname>Str&#x000f6;m</surname><given-names>O</given-names></name><name><surname>Robbins</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA)</article-title><source>Osteoporos Int</source><year>2012</year><volume>23</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">21286686</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>YC</given-names></name><name><surname>Lee</surname><given-names>YK</given-names></name><name><surname>Lim</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Physicians' attitudes to contemporary issues on osteoporosis management in Korea</article-title><source>J Bone Metab</source><year>2014</year><volume>21</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">25006571</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soong</surname><given-names>YK</given-names></name><name><surname>Tsai</surname><given-names>KS</given-names></name><name><surname>Huang</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan</article-title><source>Osteoporos Int</source><year>2013</year><volume>24</volume><fpage>511</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">22588182</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>RG</given-names></name><name><surname>Watts</surname><given-names>NB</given-names></name><name><surname>Ebetino</surname><given-names>FH</given-names></name><etal/></person-group><article-title>Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy</article-title><source>Osteoporos Int</source><year>2008</year><volume>19</volume><fpage>733</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">18214569</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilezikian</surname><given-names>JP</given-names></name></person-group><article-title>Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis</article-title><source>Am J Med</source><year>2009</year><volume>122</volume><fpage>S14</fpage><lpage>S21</lpage><pub-id pub-id-type="pmid">19187808</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamatari</surname><given-names>M</given-names></name><name><surname>Koto</surname><given-names>S</given-names></name><name><surname>Ozawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate</article-title><source>J Bone Miner Metab</source><year>2007</year><volume>25</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">17704995</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kertes</surname><given-names>J</given-names></name><name><surname>Dushenat</surname><given-names>M</given-names></name><name><surname>Vesterman</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Factors contributing to compliance with osteoporosis medication</article-title><source>Isr Med Assoc J</source><year>2008</year><volume>10</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">18494234</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weycker</surname><given-names>D</given-names></name><name><surname>Macarios</surname><given-names>D</given-names></name><name><surname>Edelsberg</surname><given-names>J</given-names></name><etal/></person-group><article-title>Compliance with osteoporosis drug therapy and risk of fracture</article-title><source>Osteoporos Int</source><year>2007</year><volume>18</volume><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">17021945</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cramer</surname><given-names>JA</given-names></name><name><surname>Amonkar</surname><given-names>MM</given-names></name><name><surname>Hebborn</surname><given-names>A</given-names></name><etal/></person-group><article-title>Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><fpage>1453</fpage><lpage>1460</lpage><pub-id pub-id-type="pmid">16197664</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YK</given-names></name><name><surname>Nho</surname><given-names>JH</given-names></name><name><surname>Ha</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Persistence with intravenous zoledronate in elderly patients with osteoporosis</article-title><source>Osteoporos Int</source><year>2012</year><volume>23</volume><fpage>2329</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">22179417</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cramer</surname><given-names>JA</given-names></name><name><surname>Gold</surname><given-names>DT</given-names></name><name><surname>Silverman</surname><given-names>SL</given-names></name><etal/></person-group><article-title>A systematic review of persistence and compliance with bisphosphonates for osteoporosis</article-title><source>Osteoporos Int</source><year>2007</year><volume>18</volume><fpage>1023</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">17308956</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>DT</given-names></name><name><surname>Martin</surname><given-names>BC</given-names></name><name><surname>Frytak</surname><given-names>JR</given-names></name><etal/></person-group><article-title>A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis</article-title><source>Curr Med Res Opin</source><year>2007</year><volume>23</volume><fpage>585</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">17355739</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siris</surname><given-names>ES</given-names></name><name><surname>Harris</surname><given-names>ST</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases</article-title><source>Mayo Clin Proc</source><year>2006</year><volume>81</volume><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">16901023</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>SL</given-names></name><name><surname>Gold</surname><given-names>DT</given-names></name></person-group><article-title>Compliance and persistence with osteoporosis therapies</article-title><source>Curr Rheumatol Rep</source><year>2008</year><volume>10</volume><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">18460266</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>SL</given-names></name><name><surname>Schousboe</surname><given-names>JT</given-names></name><name><surname>Gold</surname><given-names>DT</given-names></name></person-group><article-title>Oral bisphosphonate compliance and persistence: a matter of choice?</article-title><source>Osteoporos Int</source><year>2011</year><volume>22</volume><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">20458571</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziller</surname><given-names>V</given-names></name><name><surname>Kostev</surname><given-names>K</given-names></name><name><surname>Kyvernitakis</surname><given-names>I</given-names></name><etal/></person-group><article-title>Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database</article-title><source>Int J Clin Pharmacol Ther</source><year>2012</year><volume>50</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">22541835</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziller</surname><given-names>V</given-names></name><name><surname>Wetzel</surname><given-names>K</given-names></name><name><surname>Kyvernitakis</surname><given-names>I</given-names></name><etal/></person-group><article-title>Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene</article-title><source>Climacteric</source><year>2011</year><volume>14</volume><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">20964548</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Alarm clock will ring, when it reaches target day.</title></caption><graphic xlink:href="jbm-23-51-g001"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline characteristics of both groups</title></caption><graphic xlink:href="jbm-23-51-i001"/><table-wrap-foot><fn><p>BMI, body mass index.</p></fn></table-wrap-foot></table-wrap></floats-group></article>